| 04.10.18 | Selecta slips on gout data despite rosy spin; vTv's Pfizer castoff azeliragon flops in phase 3

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

6 jahre vor

Html
Text

To view this email as a web page, click here

This week's sponsor is TD2.
	6 Signs You Need a New CRO for Your Preclinical Research Are your preclinical studies where they deserve to be? If progress has stalled, maybe it's your CRO that's the problem...not you. Learn these six telltale signs it's time to switch. Fast-Track Your Research with TD2.

Today's Rundown

Selecta slumps as interim gout data gets frosty reception vTv's azeliragon fails to improve Alzheimer's symptoms in phase 3 Frazier Healthcare Partners closes $780M growth buyout fund Novartis offloads failed cancer drug to Oncology Venture Promethera buys TNF drug to boost cell therapy NASH strategy FDA moves the goal line on AbbVie's endometriosis drug elagolix Ayala notches up $17M in financing to push BMS drug into phase 2 FDA directive restricts sale of Bayer's Essure device

Featured Story

Selecta slumps as interim gout data gets frosty reception

Tuesday, April 10, 2018

Selecta Biosciences has posted three-month data on SEL-212 in chronic severe gout. The biotech painted data from the ongoing phase 2 trial as positive for the prospects of SEL-212, but the outside world took a different view, sending Selecta’s stock down by more than 20% premarket.

This week's sponsor is Deloitte.

vTv's azeliragon fails to improve Alzheimer's symptoms in phase 3

Monday, April 9, 2018

Another day, another Alzheimer's treatment bites the dust. This time, it's vTv Therapeutics' azeliragon, which missed both of its co-primary endpoints in a phase 3 trial of patients with mild Alzheimer's.

Frazier Healthcare Partners closes $780M growth buyout fund

Tuesday, April 10, 2018

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will be used to help established companies accelerate their growth.

Novartis offloads failed cancer drug to Oncology Venture

Tuesday, April 10, 2018

Oncology Venture has licensed a once-failed cancer drug from Novartis. The Swedish biotech picked up small molecule multi-kinase inhibitor dovitinib after an analysis of historic trial data suggested its drug response predictor will increase the likelihood of success.

Promethera buys TNF drug to boost cell therapy NASH strategy

Tuesday, April 10, 2018

Promethera Biosciences has stepped up its NASH plans with the takeover of Baliopharm. The buyout gives Promethera control of a TNF receptor 1 inhibitor it hopes will amplify the effects of cell therapy HepaStem.

FDA moves the goal line on AbbVie's endometriosis drug elagolix

Tuesday, April 10, 2018

The FDA is pushing back the PDUFA date for AbbVie and Neurocrine's drug for endometriosis-linked pain to Q3, saying it needs more time to review the results of liver function tests.

Ayala notches up $17M in financing to push BMS drug into phase 2

Tuesday, April 10, 2018

Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing. The cancer startup says its lead candidate will start a phase 2 trial in rare cancer adenoid cystic carcinoma later this year.

FDA directive restricts sale of Bayer's Essure device

Monday, April 9, 2018

The FDA is using a "unique type of restriction" to make sure only providers and facilities that inform patients about the risks and benefits of Bayer's Essure birth control device may offer it.

This week's sponsor is Sensors Expo.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] The Future of Life Sciences Events Management

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] 2018 Life Sciences Trends

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.